219.69USD+0.17%Mkt Cap: —P/E: —1d ago
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
Company
Market Cap—
Enterprise Value38.49B $
Revenue (TTM)10.03B $
Gross Profit7.85B $
Net Income (TTM)834.60M $
Revenue/Share68.19 USD
Last Price219.69 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees7.5K
CountryGB
SectorHealthcare
IndustryDrug Manufacturers - General
ISINUS09062X1037
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA11.46
EV/Revenue3.84
P/S—
P/B1.67
EPS (TTM)—
EPS (Forward)—
52W Range
205.4876% of range224.30
52W High224.30 USD
52W Low205.48 USD
Profitability
Gross Margin78.32%
Oper. Margin25.06%
EBITDA Margin33.50%
Profit Margin8.32%
ROE4.58%
ROA5.21%
Growth
Revenue Growth3.40%
Earnings Growth-84.80%
Cash Flow & Leverage
Operating CF2.88B $
CapEx (TTM)—
FCF Margin12.63%
FCF Yield—
Net Debt7.07B $
Net Debt/EBITDA2.10
Balance Sheet
Debt/Equity44.33
Current Ratio1.86
Quick Ratio0.94
Book Value/Sh127.61 USD
Cash/Share8.697 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float147.22M
Insiders0.19%
Institutions99.57%
Technical
SMA 50—
SMA 200—
Beta0.16
S&P 52W Chg20.80%
Avg Vol (30d)791
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—